Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 1/2 1

Status

Unknown 5

Sponsor Class

OTHER 954INDUSTRY 273NIH 101NETWORK 68OTHER_GOV 18UNKNOWN 5FED 1

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 3Thoracic 1Gynecologic 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1

Interventions

S 1 (combination) 12Capecitabine 11Paclitaxel 9Cisplatin 9apatinib 8Oxaliplatin 8pyrotinib 6nimotuzumab 6130-nm albumin-bound paclitaxel 6titanium silicide 5sintilimab 5camrelizumab 5anlotinib 5Etoposide 5Docetaxel 5Carboplatin 5Trastuzumab 4Radiotherapy, Intensity-Modulated 4Irinotecan 4Bevacizumab 4Albumin-Bound Paclitaxel 4nedaplatin 3Vinorelbine 3Temozolomide 3Tegafur 3Taxes 3Radiosurgery 3Gemcitabine 3Fluorouracil 3Epirubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × UNKNOWN × Carboplatin × Clear all
NCT04683198 2020-12-24

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

ChineseAMS

Phase 2 Unknown
69 enrolled
Thoracic

Small Cell Lung Carcinoma

NCT04661696 2020-12-10

Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.

ChineseAMS

Phase 2 Unknown
75 enrolled
Gynecologic

Ovarian Neoplasms

NCT03735082 2018-11-08

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
29 enrolled
Breast

Breast Neoplasms

NCT02041338 2014-11-25

Study of Optimizing Neoadjuvant Regimens in Subtypes of Breast Cancer

ChineseAMS

Phase 2 Unknown
200 enrolled
Breast

Breast Neoplasms

NCT01276769 2011-11-16

Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer

ChineseAMS

Phase 2 Unknown
80 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡